Richter BioLogics Inaugurates State-of-the-Art Biopharmaceutical Plant in Bovenau

• Richter BioLogics inaugurated a new cGMP facility in Bovenau on September 13, 2024.

• The facility, spanning 10,000 square metres, will enhance the company’s production capacity for protein-based and plasmid DNA-based products.

Richter BioLogics, the microbial biologics arm of Gedeon Richter Plc, officially opened its new cGMP facility in Bovenau on September 13, 2024. The inauguration ceremony was attended by notable figures including Daniel Günther, Minister-President of Schleswig-Holstein, and Daniel Ambrock, Mayor of Bovenau. Representing Gedeon Richter Plc were Erik Bogsch, Lifetime Honorary Chairman, Dale Martin, Member of the Supervisory Board, and Dr. Erik Bogsch, Head of the Biotechnology Business Unit, alongside Dr. Kai Pohlmeyer, CEO, and Johannes Salzbrunn, COO of Richter BioLogics.

The new facility marks one of Richter BioLogics’ largest investments in the last decade. It features cutting-edge technology designed for both clinical and large-scale commercial production of biopharmaceuticals. The 10,000 square metre plant includes new 300L and 1500L production lines, which will enable the manufacture of up to 120 batches per year. The facility also houses large analytical laboratories, warehousing, and technical areas.

Dr. Kai Pohlmeyer, Managing Director at Richter BioLogics, emphasised, “Putting the plant into operation represents a major milestone in the implementation of Richter BioLogics’ growth strategy. With this investment, we have positioned ourselves as a key player in meeting global market demand.”

The facility is expected to create over 200 new jobs by the end of 2024, doubling the current number of local employees to more than 400. Dr. Erik Bogsch, Head of the Biotechnology Business Unit of Gedeon Richter, noted, “This investment demonstrates a strong commitment to the future of Richter BioLogics, innovation, and GMP manufacturing of biopharmaceuticals made in Germany.”